* Tonix Pharmaceuticals Holding Corp TNXP.OQ TNXP.O is
expected to show a rise in quarterly revenue when it reports
results on August 14 (estimated) for the period ending June
30 2024
* The Chatham New Jersey-based company is expected to
report
revenue of $3.5 million, according to the mean estimate from 3
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Tonix Pharmaceuticals
Holding
Corp is for a loss of $3.27 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Tonix
Pharmaceuticals Holding Corp is $11.00, above its last closing
price of $0.48.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -12.38 -12.48 -5.76 Beat 53.8
Dec. 31 2024 -55.70 -52.59 -27.52 Beat 47.7
Sep. 30 2023 -47.04 -47.68 -58.56 Missed -22.8
Jun. 30 2023 -88.09 -88.16 -85.76 Beat 2.7
Mar. -88.39 -97.00 -1.04 Missed -7.2
31 2023 hundred
Dec. 31 2022 -1.08 -1.72 -1.12 Beat 34.9
hundred hundred hundred
Sep. 30 2022 -1.96 -2.04 -1.38 Beat 32.4
hundred hundred hundred
Jun. 30 2022 -2.89 -2.89 -2.44 Beat 15.6
hundred hundred hundred
This summary was machine generated August 12 at 11:20 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)